Commissariat a L'energie Atomique

Commissariat &#xc0; L'&#xc9;nergie Atomique Et Aux &#xc9;nergies Alternatives

Assistance Publique-hopitaux De Paris

Bio-rad Pasteur

Bio Modeling Systems Ou Bmsystems

Macopharma

Jean-Philippe Deslys

Emmanuel Comoy

Jacques Grassi

Edgardo Delfino Carosella

François Iris

Franck Mouthon

François Desgrandchamps

Nathalie Rouas-Freiss

Mathieu Charveriat

Pascal Wodling

Joël Le Maoult

Corinne Lasmezas

Vincent Beringue

Michel Rastorgoueff

Jérôme Verine

Chryslain Sumian

Diana Tronik-Le Roux

Francois Iris

Nina Jaffre

Nathalie Lescoutra

Embodiments of the disclosure pertain to the field of HLA-G molecules and their therapeutic use. The disclosure pertains to new HLA-G isoforms, that is to say new RNA transcripts and proteins deriving from the HLA-G gene, pharmaceutical composition comprising thereof, as well as primers specific of these transcripts and antibodies specific of these proteins. The disclosure further pertains to the diagnostic or therapeutic use of these molecules.

HLA-G transcripts and isoforms and their uses

The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-&#x3b2;-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-&#x3b2;-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.

Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs

The invention relates to a method for diagnosing a transmissible spongiform subacute encephalopathy (TSSE) caused by an unconventional transmissible agent (UTA) or prion. The method involves treating a sample suspected of containing a prion with proteinase K for a time and under conditions that completely degrade normal prion protein (Prp-sen), but which only partially digest abnormal prion protein (PrP-res) so that all or some of the octapeptide motif repeats comprising P(H/Q)GGG(-/T)WGQ (SEQ ID NO: 1) in the abnormal prion protein (Prp-res) are retained.

Method for diagnosing a transmissible spongiform subacute encephalopathy caused by an unconventional transmissible agent strain in a biological sample

Method for diagnosing a transmissible spongiform subacute encephalyopathy caused by an unconventional transmissible agent strain in a biological sample

The invention concerns a method for screening substances capable of having therapeutic action in the treatment of transmissible subacute spongiform encephalopathy (TSSE) or prion diseases comprising a step of isolating the PrPres, from the spleen, methods for isolating the PrPres, particularly adapted to said screening method and their applications, in particular for detecting PrPres.

Method for screening substances with therapeutic action in the treatment of transmissable subacute spongiform encephalopathies

The invention relates to a device for collecting a soft biological sample and to a method for using the same. The device comprises a hollow cylindrical body ( ) with two openings ( A, B), one at each end, wherein a piston ( ) with a rod ( ) is inserted via a first end and the piston-and-rod assembly can be displaced back and forth inside the hollow cylindrically ( ), the opening in the second end ( B) of the hollow cylindrical body ( ) has a slicing edge ( B) and this second end carries a cutting wire arranged across its opening.

Device and method for taking biological sample

The invention concerns a method for purifying PrPres from a biological sample to be used for qualitative and/or quantitative determination of the PrPres in said sample. The method essentially consists in: (1) incubating, during 30 seconds to 2 hours, at a temperature less than 80&deg; C., said biological sample with a buffer solution A comprising at least a surfactant in an amount ranging between a quarter and four times the weight of the biological sample and optionally a protease, to form a suspension S ; (2) adding to said suspension S resulting from (1) a buffer solution B in an amount sufficient for thinning said suspension, which buffer solution B consists of a solvent or mixture of solvents, which does not solubilize the PrPres and has a constant dielectric ranging between 10 and 25; (3) centrifuging the suspension S resulting from step (2); and (4) solubilizing said pellet in a buffer solution C comprising at least a surfactant and/or at least a chaotropic agent, at a temperature ranging between room temperature and 100&deg; C.

Method for purifying PrPres from a biological sample and applications

Growing community of inventors

Le Chesnay, France

Jean-Philippe Deslys